Katherine Collins, Associate, Patent Attorney (Life Sciences) at IP firm Mewburn Ellis
25 April 2024NewsBiotechKatherine Collins

Meeting the cell and gene therapy scale-up challenge

Improving patient access is a UN goal but for companies transitioning from trials to full-scale production, IP is essential, explains Katherine Collins of Mewburn Ellis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
17 August 2026   Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.
Biotech
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.
Biotech
20 July 2026   The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.